Apceth starts Phase I/II study with autologous stem cells for pAOD
This article was originally published in Scrip
Executive Summary
German biotech company, Apceth, has started a Phase I/II study for its somatic cell therapy, MSC-Apceth, for the treatment of peripheral arterial occlusive disease (pAOD), initial results from which are expected mid-2012.